Dentons accompanied Bpifrance Large Ventures in a 39M€ Series C financing round of ENYO Pharma, a Lyon-based biopharmaceutical company developing innovative therapies for kidney failure-related diseases.

This transaction was co-led by OrbiMed and Morningside Ventures, with the participation of other existing investors including Andera Partners and Bpifrance InnoBio.

This financing will support the phase 2 trial of Vonafexor, a drug candidate for kidney disease, as well as operations and R&D until the first semester 2026.

The Dentons Paris team was composed of Olivia Guéguen (partner), Pierre-Marie Gallo (associate) and Charlotte Berger (associate).

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com